Eris Lifesciences Share Price

Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.As of 30 May 2026, Eris Lifesciences share price is ₹1,394.00. The stock opened at ₹1,350.80, compared to its previous close of ₹1,350.80. During today's trading session, Eris Lifesciences share price moved in the range of ₹1,350.80 to ₹1,403.00, with an average price of ₹1,376.90 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,350.80 and a high of ₹1,403.00. On the performance front, Eris Lifesciences share price has declined by 12.31% over the last six months and is down 13.41% on a year-on-year basis.

The market capitalization of Eris Lifesciences is ₹19,374 Crs, with a P/E ratio of 29.9 and a dividend yield of 0.52%.